BackHEXO Overview

HEXO EBIT

Latest ebit for HEXO: $-240M, below the Healthcare sector average of $22B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$120.72M
9.22% YoY

As of Apr 30, 2023

Annual EBIT (TTM)

-$244.77M
12.64% YoY

Trailing 12 months ending Apr 30, 2023

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

HEXO (HEXO) FAQ

As of the most recent data (April 2023), HEXO shows a EBIT of $-240M. That compares with $-280M in the prior-year period — up 12.6% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, HEXO's EBIT is now $-240M (was $-280M) — a 12.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether HEXO is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. HEXO is at $-240M, which is lower that average. That is roughly 101.1% below the sector mean. Use the comparison chart on this page to see how HEXO stacks up against individual peers as well.

Tracking HEXO's ebit over time shows whether HEXO is scaling, shrinking, or reshaping that part of the business. The current reading is $-240M That compares with $-280M in the prior-year period — up 12.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has HEXO's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-240M) with ownership activity and broader fundamentals.